Fractyl Health (GUTS) Chardan's 8th Annual Genetic Medicines Conference summary

Strategic focus and differentiation

• Targeting obesity and type 2 diabetes by aiming to eradicate disease, not just manage it.

• Developing therapies that address root causes, including a duodenal device (Revita) and a one-time pancreatic gene therapy (Rejuva).

• Revita is approved in Europe, reimbursed in Germany, and in late-stage US development.

• Rejuva is expected to enter clinical trials in 2025, with strong preclinical data versus GLP-1 drugs.

• Management has deep experience in biotech, gene therapy, and medical devices, with $102M cash as of June.

Market landscape and unmet needs

• GLP-1 drugs are effective for weight loss but have high discontinuation rates and rapid weight regain.

• Only about half of obese patients are likely to use chronic medications, leaving a large unmet need.

• Real-world data show less than 50% of GLP-1 users remain on therapy at 12 weeks, with significant weight regain after stopping.

• Insurers face challenges with reimbursement due to poor long-term adherence and outcomes.

Revita device: clinical progress and data

• Revita targets the duodenal mucosa to reset gut-brain metabolic signals, aiming for durable weight maintenance.

• European registry data show 13% total body weight loss and significant A1c reduction at one year.

• Revita pivotal US study (Remain-1) is underway, with a planned midpoint analysis in Q2 2025.

• FDA Breakthrough Device Designation for both obesity and type 2 diabetes indications.

• Patients prefer Revita to avoid adding more medications or starting insulin.